Episode 8 – EMA Guidanceon Anonymisation and Redaction of RMPs

In this episode, we discuss the latest EMA guidance on anonymising and redacting Risk Management Plans (RMPs), published on 11 April 2025.
EMA published core recommendations in the document "Guidance on anonymisation of protected personal data and assessment of commercially confidential information during the preparation and redaction of RMPs (EMA/63692/2025 Rev. 3)"—focusing on how to handle personal data (PD)and commercially confidential information (CCI) before RMPs are submitted and made public.

🎯 In this episode, you’ll learn:

• Why early planning for anonymisation and redaction is now more important than ever.
• What counts as personal data and CCI—and what absolutely must not be redacted.
• Step-by-step requirements for post-CHMP opinion redacted submissions.
• Common mistakes made by MAHs and how to avoid them.

If you're preparing an RMP for submission—or reviewing your redaction practices—this episode breaks down what matters most, and how to get it right the first time.

📌 Perfect for: Pharmacovigilance professionals, MAHs,and anyone involved in RMP preparation or compliance in the EU.

Link: https://www.ema.europa.eu/system/files/documents/regulatory-procedural-guideline/anonymisation-personal-data-assessment-commercially-confidential-information-during-preparation-rmps-en.pdf